[{"data":1,"prerenderedAt":224},["ShallowReactive",2],{"story-206640-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":38,"questions":39,"relatedArticles":64,"body_color":222,"card_color":223},"206640",null,"Obesity Drug Market Consolidation Accelerates | Novo Nordisk & Eli Lilly Dominance Strengthens After Zealand Setback","- Zealand Pharma stock crashes 25-47% YTD as survodutide shows 19% discontinuation rate; market leadership solidifies around proven GLP-1 competitors with superior tolerability profiles",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37],"https:\u002F\u002Fwww.statnews.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002FAdobeStock_415492512_Editorial_Use_Only-645x645.jpeg","https:\u002F\u002Fqtxasset.com\u002Fcdn-cgi\u002Fimage\u002Fw=384,h=216,f=auto,fit=crop,g=0.5x0.5\u002Fhttps:\u002F\u002Fqtxasset.com\u002Fquartz\u002Fqcloud5\u002Fmedia\u002Fimage\u002FImage%20%2874%29.jpg?VersionId=iCcjl2XqznLgrdQCyEo0N8TO.qO1Pzmk","https:\u002F\u002Fwww.boehringer-ingelheim.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Fmeta\u002Fpublic\u002F2026-06\u002FBoehringer_Healthcare_MiddleAge_Consult.jpg","https:\u002F\u002Fimages.wsj.net\u002Fim-64155432?width=700&height=465","https:\u002F\u002Fetimg.etb2bimg.com\u002Fthumb\u002Fmsid-131580073,width-1200,height-900,resizemode-4\u002F.jpg","https:\u002F\u002Fpharmaphorum.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Fx_large\u002Fpublic\u002F2023-11\u002FBoehringer_building-960-540.jpg?itok=vnBSZ4_H","https:\u002F\u002Fwww.clinicaltrialvanguard.com\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002Fsurvodutide-phase-iii-trial-shows-34-visceral-fat-63-liver-f-1250x715.png","https:\u002F\u002Fimage.cnbcfm.com\u002Fapi\u002Fv1\u002Fimage\u002F108226739-1763385616870-gettyimages-2221165792-INDIA_WEGOVY.jpeg?v=1763385675&w=1600&h=900","https:\u002F\u002Fpharmatimes.com\u002Fwp-content\u002Fuploads\u002F2023\u002F08\u002Fliver.jpg","https:\u002F\u002Fbiostock.se\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002Fvisceral-fat.webp","https:\u002F\u002Fendpoints.news\u002Fwp-content\u002Fuploads\u002F2024\u002F09\u002FBoehringer-Ingelheim-shutterstock-social1.jpg","https:\u002F\u002Fimgproxy.watchmedier.dk\u002Fwatchmedier\u002Fresize:fill:3840:0:0\u002Fplain\u002Fhttps:\u002F\u002Fphotos.watchmedier.dk\u002FImages\u002F19368184\u002Fhq1794\u002FALTERNATES\u002Fmaster-3_2\u002Fjefferies-fincl-debt","https:\u002F\u002Fwww.clinicaltrialvanguard.com\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002Freading-the-synchronize-masld-phase-3-trial-publication-clos-1250x715.png","https:\u002F\u002Fhogo.sgp1.digitaloceanspaces.com\u002Fmacaubusiness\u002Fwp-content\u002Fuploads\u002F2026\u002F05\u002FFusion-cuisine-scaled.jpg","https:\u002F\u002Fcdn.sanity.io\u002Fimages\u002F0vv8moc6\u002Fajmc\u002F141b029fa189109932c5f3649fdf85c83279b057-1200x640.png","https:\u002F\u002Fwww.manilatimes.net\u002Fmanilatimes\u002Fuploads\u002Fimages\u002F2026\u002F06\u002F08\u002F1088917.png","https:\u002F\u002Fimgproxy.watchmedier.dk\u002Fwatchmedier\u002Fresize:fill:3840:0:0\u002Fplain\u002Fhttps:\u002F\u002Fphotos.watchmedier.dk\u002FImages\u002F19367453\u002Fm1ap81\u002FALTERNATES\u002Fmaster-3_2\u002Fadam-steensberg-","https:\u002F\u002Fts2.tech\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002Ffeatured-image-featured-413.jpg","https:\u002F\u002Fmedia.springernature.com\u002Fm685\u002Fspringer-static\u002Fimage\u002Fart%3A10.1038%2Fs41591-026-04479-3\u002FMediaObjects\u002F41591_2026_4479_Fig1_HTML.png","https:\u002F\u002Fcdn.sanity.io\u002Fimages\u002F0vv8moc6\u002Fhcplive\u002F8fe11b4b3cdea59672b753650c5b47d8ac3ee980-1200x628.png","https:\u002F\u002Fwww.manilatimes.net\u002Fmanilatimes\u002Fuploads\u002Fimages\u002F2026\u002F06\u002F08\u002F1088918.png","https:\u002F\u002Fwww.reuters.com\u002Fresizer\u002Fv2\u002FGH27N2ZGX5NMVD2SH6YJKUERXA.jpg?auth=162f9290e837b2975443ecce7cdca8d952d36abe88d114aea38646f26cf62cb8&height=1005&width=1920&quality=80&smart=true","https:\u002F\u002Fcdn.thepharmaletter.com\u002Ffiles\u002F2022\u002F12\u002Fc9814cf0-771b-11ed-b946-ad12b6fcbb1e-boehringer-ingelheim-big.jpg","https:\u002F\u002Fmedia-cdn.socastsrm.com\u002Fuploads\u002Fstation\u002F1955\u002FfbShare.png?r=67810","https:\u002F\u002Fimages.mktw.net\u002Fim-14353748?width=1260&height=840","https:\u002F\u002Fassets.bwbx.io\u002Fimages\u002Fusers\u002FiqjWHBFdfxIU\u002FiDk0sMWgRl8A\u002Fv0\u002F-1x-1.webp","https:\u002F\u002Fwww8.gmanews.tv\u002Fwebpics\u002Fv3\u002F2012\u002F11\u002Fthumb-wellness-weightloss1.jpg","https:\u002F\u002Fimg-s-msn-com.akamaized.net\u002Ftenant\u002Famp\u002Fentityid\u002FAA253jbj.img?w=1536&h=864&m=4&q=98","**Market Context**: Zealand Pharma's experimental obesity drug survodutide experienced a critical setback on June 8, 2026, when Phase 3 clinical trial data revealed a 19% patient discontinuation rate due to gastrointestinal adverse events—compared to just 2.9% on placebo—with over 40% of patients experiencing vomiting. This safety signal directly contradicts the drug's efficacy profile (16.6% average weight loss vs. 3.2% placebo over 76 weeks) and has triggered a 25-26% single-day stock collapse for the Danish pharmaceutical company, compounding year-to-date losses to approximately 47%. The discontinuation rate represents the second major setback for Zealand in three months, following disappointing petrelintide trial data in March 2026.\n\n**Competitive Landscape Implications**: The obesity treatment market, valued at multi-billion dollars globally, remains dominated by **Novo Nordisk** (semaglutide\u002FWegovy, Ozempic) and **Eli Lilly** (tirzepatide\u002FZepbound, Mounjaro), which have demonstrated superior tolerability profiles in clinical practice. Citi analysts explicitly noted that survodutide's 19% discontinuation rate \"is not a rounding error,\" with nausea, vomiting, diarrhea, and constipation incidence levels exceeding commercially viable thresholds against established competitors. Barclays characterized the safety-tolerability profile as \"disappointing\" despite positive signals in body composition and liver fat reduction (34% visceral fat reduction, 63.1% liver fat reduction). This creates a critical market dynamic: while survodutide demonstrated meaningful metabolic benefits—particularly in treating metabolic dysfunction-associated fatty liver disease (MASLD) with 84.2% of patients achieving 30%+ liver fat reduction—the tolerability gap makes commercial viability questionable.\n\n**Emerging Market Dynamics**: The clinical setback accelerates market consolidation around proven therapies. Intensifying competition from **Amgen**, **AstraZeneca**, and **Altimmune** (developing dual GLP-1\u002Fglucagon therapies) indicates the market is shifting from pure weight-loss percentages toward differentiation through tolerability, lean mass preservation, and organ-specific fat reduction. Zealand's CEO has advocated for this reframing, arguing the industry has become obsessed with \"weight loss olympics,\" but the market has rejected this positioning when safety profiles don't support it. For investors and market participants, this signals that first-mover advantage in obesity treatment has solidified around companies with proven safety data, making late-stage entrants face significantly higher regulatory and commercial hurdles. The partnership between Boehringer Ingelheim and Zealand may face reassessment, potentially affecting development timelines and commercialization strategies for survodutide globally.",[40,43,46,49,52,55,58,61],{"title":41,"answer":42,"author":5,"avatar":5,"time":5},"What is the market size and competitive intensity in obesity drug treatment?","The obesity drug market represents a multi-billion-dollar opportunity with intensifying competition from multiple pharmaceutical companies. Market leaders Novo Nordisk and Eli Lilly dominate with proven GLP-1 therapies, while competitors including Amgen, AstraZeneca, and Altimmune are developing alternative approaches. The market has shifted focus from pure weight-loss percentages toward tolerability, lean mass preservation, and organ-specific fat reduction as key differentiators. Zealand's setback indicates that late-stage entrants face significantly higher regulatory and commercial hurdles, with first-mover advantage solidifying around companies with proven safety data.",{"title":44,"answer":45,"author":5,"avatar":5,"time":5},"How might Zealand's setback affect the Boehringer Ingelheim partnership?","The clinical setback may trigger reassessment of the Boehringer Ingelheim-Zealand partnership, potentially affecting development timelines and commercialization strategies for survodutide globally. Boehringer acquired exclusive development and commercialization rights in 2011 with Zealand entitled to royalty payments on global revenue. The 19% discontinuation rate and investor concerns about commercial viability could lead to reduced investment, delayed development timelines, or strategic repositioning of the drug for niche indications (such as MASLD treatment) rather than broad obesity treatment. This represents the second major setback for Zealand in three months, compounding pressure on the partnership.",{"title":47,"answer":48,"author":5,"avatar":5,"time":5},"What does Zealand's CEO mean by shifting focus from 'weight loss olympics' to tolerability?","Zealand's CEO advocated for reframing the obesity drug market away from pure weight-loss percentages toward tolerability and how weight loss is achieved. This positioning acknowledges that survodutide's 16.6% average weight loss is comparable to competitors but doesn't justify the 19% discontinuation rate. The market has rejected this reframing, indicating that investors and physicians prioritize proven safety profiles over marginal efficacy improvements. The 'weight loss olympics' comment reflects frustration that the market hasn't valued survodutide's metabolic benefits (liver fat reduction, lean mass preservation) sufficiently to offset tolerability concerns.",{"title":50,"answer":51,"author":5,"avatar":5,"time":5},"How does Zealand's stock decline impact royalty payments and partnership dynamics?","Boehringer Ingelheim acquired exclusive development and commercialization rights to survodutide in 2011, with Zealand entitled to royalty payments on global revenue. Zealand's 47% year-to-date stock decline reflects investor concerns about the company's pipeline and future revenue prospects. If survodutide fails to achieve significant market adoption due to tolerability concerns, Zealand's royalty revenue will be substantially lower than anticipated, potentially forcing the company to reassess its partnership with Boehringer. Boehringer may also reassess development timelines and commercialization strategies, potentially limiting investment in survodutide marketing and distribution. This uncertainty creates opportunities for e-commerce sellers to fill the gap with alternative products, as pharmaceutical companies may deprioritize obesity treatment investments pending clinical and commercial clarity.",{"title":53,"answer":54,"author":5,"avatar":5,"time":5},"Why did Zealand Pharma's stock drop 25-47% after survodutide trial results?","Zealand's stock collapsed because Phase 3 trial data revealed a 19% patient discontinuation rate due to gastrointestinal side effects (nausea, vomiting, diarrhea), compared to 2.9% on placebo. While the drug achieved 16.6% average weight loss—comparable to competitors—the high discontinuation rate raised serious questions about commercial viability. Citi analysts emphasized this 19% rate 'is not a rounding error,' indicating the tolerability profile falls below commercially acceptable thresholds against established competitors like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide. The stock decline reflects investor concerns about the company's pipeline and competitive positioning in the lucrative obesity treatment market.",{"title":56,"answer":57,"author":5,"avatar":5,"time":5},"How does survodutide's safety profile compare to Novo Nordisk and Eli Lilly obesity drugs?","Survodutide's 19% discontinuation rate due to gastrointestinal adverse events significantly exceeds the tolerability profile of established competitors. Novo Nordisk's semaglutide (Wegovy, Ozempic) and Eli Lilly's tirzepatide (Zepbound, Mounjaro) have demonstrated superior safety profiles in clinical practice, making them the market leaders. While survodutide showed promising metabolic benefits—reducing liver fat by up to 63.1% and visceral fat by 34%—these advantages don't offset the tolerability disadvantage. Barclays analysts characterized survodutide's safety-tolerability profile as 'disappointing' despite positive body composition signals, indicating the market prioritizes proven safety over marginal efficacy improvements.",{"title":59,"answer":60,"author":5,"avatar":5,"time":5},"What does the 19% discontinuation rate mean for survodutide's regulatory approval prospects?","The 19% discontinuation rate represents a substantial safety signal that will likely trigger regulatory scrutiny from agencies like the FDA. High discontinuation rates in Phase 3 trials often require additional safety monitoring, restricted use protocols, or dose adjustments before approval. Boehringer Ingelheim and Zealand will need to conduct further analysis to determine whether dose modifications or patient selection criteria could improve tolerability without compromising efficacy. The regulatory pathway has become significantly more challenging, potentially delaying commercialization timelines and limiting the drug's market opportunity if approved with restrictions.",{"title":62,"answer":63,"author":5,"avatar":5,"time":5},"How does survodutide's metabolic benefit in liver fat reduction differentiate it from competitors?","Survodutide demonstrated significant differentiation in organ-specific fat reduction: 84.2% of patients with metabolic dysfunction-associated fatty liver disease (MASLD) achieved at least 30% liver fat reduction versus 24.3% on placebo, with 61% achieving liver fat normalization (below 5%) versus 5.7% on placebo. The drug also preserved lean muscle mass, with no more than 10.8% of body composition changes at the highest 6mg dose. Boehringer positioned this as addressing 'the intersection of obesity and liver disease,' but the tolerability issues overshadow these metabolic advantages in the competitive market.",[65,70,74,78,82,86,90,94,98,102,106,110,114,118,122,126,130,134,138,142,146,150,154,158,162,165,169,172,176,180,184,188,191,194,198,201,205,208,212,215,219],{"id":66,"title":67,"source":68,"logo":24,"time":69},1025126,"Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD","https:\u002F\u002Fwww.ajmc.com\u002Fview\u002Fsurvodutide-normalizes-liver-fat-in-61-of-patients-with-masld-in-phase-3-trial-lee-kaplan-md-phd","1H AGO",{"id":71,"title":72,"source":73,"logo":5,"time":69},1025148,"Zealand Pharma crashes 26% as obesity drug’s side effects, dropouts disappoint","https:\u002F\u002Fng.investing.com\u002Fnews\u002Fstock-market-news\u002Fzealand-pharma-crashes-26-as-obesity-drugs-side-effects-dropouts-disappoint-2547103",{"id":75,"title":76,"source":77,"logo":34,"time":69},1025125,"Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial","https:\u002F\u002Fwww.marketwatch.com\u002Fstory\u002Fzealand-pharma-loses-a-fifth-of-its-value-as-many-users-gave-up-taking-weight-loss-drug-during-trial-80293179",{"id":79,"title":80,"source":81,"logo":26,"time":69},1025147,"One in five dropped out: Analyst predicts disappointment for Zealand Pharma following new weight-loss data","https:\u002F\u002Fmedwatch.com\u002FNews\u002FPharma___Biotech\u002Farticle19367536.ece",{"id":83,"title":84,"source":85,"logo":11,"time":69},1025124,"ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update","https:\u002F\u002Fwww.fiercebiotech.com\u002Fbiotech\u002Fada-boehringer-points-survodutides-targeted-weight-loss-tolerability-questions-linger",{"id":87,"title":88,"source":89,"logo":16,"time":69},1025146,"Survodutide Phase III trial shows 34% visceral fat, 63% liver fat reduction","https:\u002F\u002Fwww.clinicaltrialvanguard.com\u002Fnews\u002Fsurvodutide-phase-iii-trial-shows-34-visceral-fat-63-liver-fat-reduction",{"id":91,"title":92,"source":93,"logo":20,"time":69},1025123,"Nearly 1 in 5 patients quit Boehringer and Zealand’s obesity shot over side effects","https:\u002F\u002Fendpoints.news\u002Fada26-19-of-phase-3-patients-quit-boehringer-obesity-shot-over-side-effects",{"id":95,"title":96,"source":97,"logo":5,"time":69},1025145,"Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD","https:\u002F\u002Fwww.ajmc.com\u002Fview\u002Femerging-data-suggest-survodutide-targets-liver-fat-more-rapidly-than-weight-loss-lee-kaplan-md-phd",{"id":99,"title":100,"source":101,"logo":28,"time":69},1025129,"Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial","https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41591-026-04479-3",{"id":103,"title":104,"source":105,"logo":5,"time":69},1025128,"Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health","https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fonce-weekly-drug-demonstrates-promising-dual-benefits-in-obesity-and-metabolic-health-302793309.html",{"id":107,"title":108,"source":109,"logo":22,"time":69},1025127,"Reading the SYNCHRONIZE-MASLD Phase 3 Trial Publication Closely","https:\u002F\u002Fwww.clinicaltrialvanguard.com\u002Fopinion\u002Freading-the-synchronize-masld-phase-3-trial-publication-closely",{"id":111,"title":112,"source":113,"logo":5,"time":69},1025149,"Zealand Pharma shares crash 26% as obesity drug side effects overshadow trial data By Investing.com","https:\u002F\u002Fin.investing.com\u002Fnews\u002Fstock-market-news\u002Fzealand-pharma-crashes-26-as-obesity-drugs-side-effects-dropouts-disappoint-5443748",{"id":115,"title":116,"source":117,"logo":27,"time":69},1025140,"Zealand Pharma Shares Sink 25% After Trial Results","https:\u002F\u002Fts2.tech\u002Fen\u002Fzealand-pharma-shares-sink-25-after-trial-results",{"id":119,"title":120,"source":121,"logo":5,"time":69},1025160,"Boehringer Ingelheim’s survodutide Phase III trial showed","https:\u002F\u002Fwww.globenewswire.com\u002Fnews-release\u002F2026\u002F06\u002F07\u002F3307741\u002F0\u002Fen\u002Fboehringer-ingelheim-s-survodutide-phase-iii-trial-showed-targeted-34-visceral-and-63-liver-fat-reduction-while-minimizing-lean-mass-loss-in-pre-specified-analysis-supporting-impro.html",{"id":123,"title":124,"source":125,"logo":13,"time":69},1025122,"Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot’s Side Effects","https:\u002F\u002Fwww.wsj.com\u002Fhealth\u002Fpharma\u002Fzealand-pharma-shares-slide-after-boehringer-study-shows-obesity-shots-side-effects-a624e7b4",{"id":127,"title":128,"source":129,"logo":5,"time":69},1025144,"Zealand Pharma (ZEAL) Stock Drops 25% After Obesity Drug Trial Shows High Drop-Out Rate","https:\u002F\u002Fcoincentral.com\u002Fzealand-pharma-zeal-stock-drops-25-after-obesity-drug-trial-shows-high-drop-out-rate",{"id":131,"title":132,"source":133,"logo":31,"time":69},1025121,"Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat","https:\u002F\u002Fwww.reuters.com\u002Fbusiness\u002Fhealthcare-pharmaceuticals\u002Fboehringer-zealands-obesity-drug-shows-promise-cutting-visceral-liver-fat-2026-06-07",{"id":135,"title":136,"source":137,"logo":33,"time":69},1025143,"Zealand Pharma shares drop 20% as obesity drug side effects raise concerns","https:\u002F\u002Fwhbl.com\u002F2026\u002F06\u002F08\u002Fzealand-pharma-shares-drop-20-as-obesity-drug-side-effects-raise-concerns",{"id":139,"title":140,"source":141,"logo":17,"time":69},1025120,"Weight loss drug maker sinks 25% after new safety data spooks investors","https:\u002F\u002Fwww.cnbc.com\u002F2026\u002F06\u002F08\u002Fweight-loss-drug-stock-zealand-pharma-data-ada.html",{"id":143,"title":144,"source":145,"logo":37,"time":69},1025142,"Boehringer's obesity drug cuts harmful belly and liver fat in late-stage trials","https:\u002F\u002Fwww.msn.com\u002Fen-us\u002Fhealth\u002Fother\u002Fboehringer-s-obesity-drug-cuts-harmful-belly-and-liver-fat-in-late-stage-trials\u002Far-AA252W3n",{"id":147,"title":148,"source":149,"logo":5,"time":69},1025141,"Zealand Pharma (ZLDPF) Shares Plunge 26% Amid Side Effect Concer","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F8904917\u002Fzealand-pharma-zldpf-shares-plunge-26-amid-side-effect-concerns",{"id":151,"title":152,"source":153,"logo":21,"time":69},1025137,"Analysts see difficult road ahead for Zealand Pharma's weight-loss candidate","https:\u002F\u002Fmedwatch.com\u002FNews\u002FPharma___Biotech\u002Farticle19368243.ece",{"id":155,"title":156,"source":157,"logo":5,"time":69},1025159,"Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis","https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Fzealand-pharma-announces-boehringer-ingelheims-183000126.html",{"id":159,"title":160,"source":161,"logo":32,"time":69},1025136,"Boehringer obesity drug shows fat loss gains but tolerability clouds ADA readout","https:\u002F\u002Fwww.thepharmaletter.com\u002Fpharma-news\u002Fboehringer-obesity-drug-shows-fat-loss-gains-but-tolerability-clouds-ada-readout",{"id":163,"title":156,"source":164,"logo":25,"time":69},1025158,"https:\u002F\u002Fwww.manilatimes.net\u002F2026\u002F06\u002F08\u002Ftmt-newswire\u002Fglobenewswire\u002Fzealand-pharma-announces-boehringer-ingelheims-survodutide-phase-iii-trial-in-people-living-with-obesity-showed-targeted-34-visceral-and-63-liver-fat-reduction-while-minimizing-lean-mass-loss-in-pre-specified-analysis\u002F2360289",{"id":166,"title":167,"source":168,"logo":19,"time":69},1025135,"Zealand Pharma's candidate takes aim at visceral fat","https:\u002F\u002Fwww.biostock.se\u002Fen\u002F2026\u002F06\u002Fzealand-pharmas-kandidat-slar-hart-mot-visceralt-fett",{"id":170,"title":156,"source":171,"logo":5,"time":69},1025157,"https:\u002F\u002Fuk.finance.yahoo.com\u002Fnews\u002Fzealand-pharma-announces-boehringer-ingelheims-183000976.html",{"id":173,"title":174,"source":175,"logo":29,"time":69},1025134,"Survodutide Shows Fat Mass Loss, Liver Fat Reductions in Patients With Obesity Without T2D","https:\u002F\u002Fwww.hcplive.com\u002Fview\u002Fsurvodutide-shows-fat-mass-loss-liver-fat-reductions-patients-obesity-without-t2d",{"id":177,"title":178,"source":179,"logo":30,"time":69},1025156,"Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity","https:\u002F\u002Fwww.manilatimes.net\u002F2026\u002F06\u002F08\u002Ftmt-newswire\u002Fglobenewswire\u002Fboehringer-ingelheims-survodutide-phase-iii-trial-showed-targeted-34-visceral-and-63-liver-fat-reduction-while-minimizing-lean-mass-loss-in-pre-specified-analysis-supporting-improved-metabolic-health-in-people-living-with-obesity\u002F2360290",{"id":181,"title":182,"source":183,"logo":5,"time":69},1025139,"Why is Zealand Pharma stock crashing today? By Investing.com","https:\u002F\u002Fin.investing.com\u002Fnews\u002Fstock-market-news\u002Fwhy-is-zealand-pharma-stock-crashing-today-93CH-5443757",{"id":185,"title":186,"source":187,"logo":12,"time":69},1025138,"Positive data from two Phase III SYNCHRONIZE obesity trials","https:\u002F\u002Fwww.boehringer-ingelheim.com\u002Fus\u002Fhuman-health\u002Fmetabolic-diseases\u002Fpositive-data-two-phase-iii-synchronize-obesity-trials",{"id":189,"title":182,"source":190,"logo":5,"time":69},1025151,"https:\u002F\u002Fza.investing.com\u002Fnews\u002Fstock-market-news\u002Fwhy-is-zealand-pharma-stock-crashing-today-93CH-4317298",{"id":192,"title":182,"source":193,"logo":5,"time":69},1025150,"https:\u002F\u002Fng.investing.com\u002Fnews\u002Fstock-market-news\u002Fwhy-is-zealand-pharma-stock-crashing-today-93CH-2547112",{"id":195,"title":196,"source":197,"logo":35,"time":69},1025133,"Boehringer Pitches Muscle-Sparing Obesity Drug in Crowded Field","https:\u002F\u002Fwww.bloomberg.com\u002Fnews\u002Farticles\u002F2026-06-07\u002Fboehringer-pitches-muscle-sparing-obesity-drug-in-crowded-field",{"id":199,"title":178,"source":200,"logo":23,"time":69},1025155,"https:\u002F\u002Fmacaubusiness.com\u002Fboehringer-ingelheims-survodutide-phase-iii-trial-showed-targeted-34-visceral-and-63-liver-fat-reduction-while-minimizing-lean-mass-loss-in-pre-specified-analysis-supporting-improved-metabo",{"id":202,"title":203,"source":204,"logo":15,"time":69},1025132,"ADA: Safety data offset efficacy for survodutide","https:\u002F\u002Fpharmaphorum.com\u002Fnews\u002Fada-safety-data-offset-efficacy-survodutide",{"id":206,"title":132,"source":207,"logo":36,"time":69},1025154,"https:\u002F\u002Fwww.gmanetwork.com\u002Fnews\u002Fscitech\u002Fscience\u002F990570\u002Fboehringer-zealand-drug-survodutide-fat\u002Fstory",{"id":209,"title":210,"source":211,"logo":10,"time":69},1025131,"New data may cast doubt on competitiveness of Boehringer’s obesity drug","https:\u002F\u002Fwww.statnews.com\u002F2026\u002F06\u002F07\u002Fboehringer-ingelheim-obesity-drug-survodutide-phase-3-data",{"id":213,"title":132,"source":214,"logo":14,"time":69},1025153,"https:\u002F\u002Fpharma.economictimes.indiatimes.com\u002Fnews\u002Fresearch-and-development\u002Fboehringer-zealands-obesity-drug-shows-promise-in-cutting-visceral-liver-fat\u002F131580073",{"id":216,"title":217,"source":218,"logo":18,"time":69},1025130,"Survodutide trial data show targeted visceral and liver fat reductions","https:\u002F\u002Fpharmatimes.com\u002Fnews\u002Fsurvodutide-trial-data-show-targeted-visceral-and-liver-fat-reductions",{"id":220,"title":182,"source":221,"logo":5,"time":69},1025152,"https:\u002F\u002Fca.investing.com\u002Fnews\u002Fstock-market-news\u002Fwhy-is-zealand-pharma-stock-crashing-today-93CH-4679095","#cdf601ff","#cdf6014d",1780939885839]